Clinical Trials
3 trialsNCT05119855 2026-02-05
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04442048 2025-12-30
COV-IMMUNO
Canadian Cancer Trials Group
Phase 3 Completed
NCT04534725 2023-08-24
C-SMART
Peter MacCallum Cancer Centre, Australia
Phase 3 Completed